✦ LIBER ✦

Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)

✍ Scribed by Pimstone, Neville R.; Canio, John B.; Chiang, Michelle H.; Kokosinski, Janet; Powell, Jerry S.; Saicheur, Theparat; Sheykhzadeh, Paul I.; Yu, Andy S.

Book ID: 124108754
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 184 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)82822-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Virologic response in re-treatment of ch

Virologic response in re-treatment of chronic hepatitis C interferon (IFN) virologic non-responders (NR) and responder-relapsers (RR): IFN induction followed by combination ribavirin: High dose IFN (780 MIU/52 weeks)

✍ Pimstone, Neville R.; Canio, John B.; Powell, Jerry S.; Kokosinski, Janet; Saich 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Ribavirin/interferon α-2b (IFN) therapy

Ribavirin/interferon α-2b (IFN) therapy is very effective in the treatment of chronic hepatitis C genotype 2&3 patients who have failed to respond virologically to IFN monotherapy

✍ Pimstone, Neville R.; Canio, John B.; Chiang, Michelle H.; Kokosinski, Janet; Po 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 188 KB

475 Sustained virological response (SVR)

475 Sustained virological response (SVR) to peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (Roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC)

✍ S. Fargion; M. Borzio; A. Maraschi; A. Cargnel 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 61 KB